- Home
- SGC vs NYXH Comparison
SGC vs NYXH Comparison
Compare SGC & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGC
- NYXH
- Stock Information
- Founded
- SGC 1920
- NYXH 2009
- Country
- SGC United States
- NYXH Belgium
- Employees
- SGC N/A
- NYXH N/A
- Industry
- SGC Apparel
- NYXH Medical/Dental Instruments
- Sector
- SGC Consumer Discretionary
- NYXH Health Care
- Exchange
- SGC Nasdaq
- NYXH Nasdaq
- Market Cap
- SGC 215.7M
- NYXH 231.0M
- IPO Year
- SGC N/A
- NYXH 2021
- Fundamental
- Price
- SGC $11.79
- NYXH $5.24
- Analyst Decision
- SGC Strong Buy
- NYXH Strong Buy
- Analyst Count
- SGC 3
- NYXH 3
- Target Price
- SGC $17.33
- NYXH $15.00
- AVG Volume (30 Days)
- SGC 42.0K
- NYXH 82.8K
- Earning Date
- SGC 11-05-2025
- NYXH 11-05-2025
- Dividend Yield
- SGC 4.74%
- NYXH N/A
- EPS Growth
- SGC N/A
- NYXH N/A
- EPS
- SGC 0.52
- NYXH N/A
- Revenue
- SGC $576,240,000.00
- NYXH $5,793,306.00
- Revenue This Year
- SGC $1.46
- NYXH $144.57
- Revenue Next Year
- SGC $3.32
- NYXH $244.36
- P/E Ratio
- SGC $22.63
- NYXH N/A
- Revenue Growth
- SGC 4.03
- NYXH 2.94
- 52 Week Low
- SGC $9.11
- NYXH $5.28
- 52 Week High
- SGC $18.48
- NYXH $11.87
- Technical
- Relative Strength Index (RSI)
- SGC 46.13
- NYXH 27.77
- Support Level
- SGC $11.60
- NYXH $5.45
- Resistance Level
- SGC $12.27
- NYXH $6.09
- Average True Range (ATR)
- SGC 0.45
- NYXH 0.26
- MACD
- SGC -0.19
- NYXH -0.04
- Stochastic Oscillator
- SGC 8.72
- NYXH 0.00
About SGC Superior Group of Companies Inc.
Superior Group Of Companies Inc designs apparel products. The company's operating segment includes Branded Products; Healthcare Apparel and Contact Centers. It generates maximum revenue from the Branded Products segment. The Branded Products segment produce and sell customized merchandising solutions, promotional products and branded uniform programs to customers.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.